CD8A and prostate cancer: In the present study, we used this technology to design a prostate cancer vaccine candidate (TENDU) containing long synthetic peptides harboring prostate cancer-derived epitopes (CD4 and CD8) from PAP, PSMA (preclinical and clinical study), and NY-ESO1 (preclinical study).